Last week, vTv Therapeutics Inc (NASDAQ:VTVT) announced that azeliragon, the company’s RAGE inhibitor in development for Alzheimer’s disease (AD) failed in Part A …
What does the future hold for Tesla (NASDAQ:TSLA) and Twitter (NYSE:TWTR)? Sell-side analysts from Bernstein and Morgan Stanley weigh in on the two tech giants, …
Yesterday, Merck (NYSE:MRK) reported data from Keytruda in combo with chemotherapy for patients with non-small cell lung cancer (NSCLC). The data was positive …
David Wong is upbeat on AMD’s sharpening competitive edge in microprocessor to graphics markets.
Shares of virtualization and data management company Sphere 3D (NASDAQ:ANY) are collapsing – down nearly 45% as of this writing. The reason?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) just riled up Wall Street today with enticing Phase 2 study results in non-small cell lung cancer (NSCLC), sending …
Cowen’s Ritu Baral’s conversations with key experts in the field with Nuplazid experience leave her positive; albeit somewhat ‘cautious’ on the impact of ACAD’s controversy.
Needham’s Rajvindra Gill sees not much of a financial impact to NVDA shares on the heels of a troublesome round of negative headlines.
Though Tim Chiang meaningfully scales back his target expectations, he still sees 60% potential upside for PTGX shares thanks to its tech platform.
Yet another analyst has weighed in on Nutanix Inc (NASDAQ:NTNX) and pushed sales forecast higher for the hyper-converged infrastructure maker. Maxim analyst Nehal Chokshi reiterated a Buy …
